The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Immunotherapy vs. chemotherapy run-in followed by pembrolizumab plus nab-paclitaxel in metastatic triple negative breast cancer (mTNBC): Results from a phase II study.
 
Alessandro Leal
Employment - Delfi Diagnostics
Stock and Other Ownership Interests - Delfi Diagnostics
Patents, Royalties, Other Intellectual Property - Delfi Diagnostics
Travel, Accommodations, Expenses - Delfi Diagnostics
 
Natalie Klar
Research Funding - Merck (Inst)
 
Apoorvi Tyagi
No Relationships to Disclose
 
Farbod Darvishian
No Relationships to Disclose
 
Maryann Kwa
No Relationships to Disclose
 
Marleen Meyers
No Relationships to Disclose
 
Yelena Novik
No Relationships to Disclose
 
Ruth Oratz
No Relationships to Disclose
 
Anastasia Zhurova
No Relationships to Disclose
 
Cindy Loomis
No Relationships to Disclose
 
Douglas Marks
No Relationships to Disclose
 
Iryna Voloshyna
No Relationships to Disclose
 
Michelle Krogsgaard
No Relationships to Disclose
 
Sylvia Adams
Consulting or Advisory Role - Cogent Biosciences
Research Funding - Amgen; Bristol-Myers Squibb; Celgene; Genentech; Merck